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Abstract
Background: Cells permissive to virus can become refractory to viral replication upon intracellular expression of
single chain fragment variable (scFv) antibodies directed towards viral structural or regulatory proteins, or virus-
coded enzymes. For example, an intrabody derived from MH-SVM33, a monoclonal antibody against a conserved
C-terminal epitope of the HIV-1 matrix protein (MAp17), was found to exert an inhibitory effect on HIV-1
replication.
Results: Two versions of MH-SVM33-derived scFv were constructed in recombinant baculoviruses (BVs) and
expressed in BV-infected Sf9 cells, N-myristoylation-competent scFvG2/p17 and N-myristoylation-incompetent
scFvE2/p17 protein, both carrying a C-terminal HA tag. ScFvG2/p17 expression resulted in an insoluble, membrane-
associated protein, whereas scFvE2/p17 was recovered in both soluble and membrane-incorporated forms. When
coexpressed with the HIV-1 Pr55Gag precursor, scFvG2/p17 and scFvE2/p17 did not show any detectable negative
effect on virus-like particle (VLP) assembly and egress, and both failed to be encapsidated in VLP. However, soluble
scFvE2/p17 isolated from Sf9 cell lysates was capable of binding to its specific antigen, in the form of a synthetic
p17 peptide or as Gag polyprotein-embedded epitope. Significant amounts of scFvE2/p17 were released in the
extracellular medium of BV-infected cells in high-molecular weight, pelletable form. This particulate form
corresponded to BV particles displaying scFvE2/p17 molecules, inserted into the BV envelope via the scFv
N-terminal region. The BV-displayed scFvE2/p17 molecules were found to be immunologically functional, as they
reacted with the C-terminal epitope of MAp17. Fusion of the N-terminal 18 amino acid residues from the scFvE2/
p17 sequence (N18E2) to another scFv recognizing CD147 (scFv-M6-1B9) conferred the property of BV-display to
the resulting chimeric scFv-N18E2/M6.
Conclusion: Expression of scFvE2/p17 in insect cells using a BV vector resulted in baculoviral progeny displaying
scFvE2/p17. The function required for BV envelope incorporation was carried by the N-terminal octadecapeptide of
scFvE2/p17, which acted as a signal peptide for BV display. Fusion of this peptide to the N-terminus of scFv
molecules of interest could be applied as a general method for BV-display of scFv in a GP64- and VSV-G-
independent manner.
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The arsenal of HIV-1 antivirals available today includes
a broad variety of drugs directed to viral targets which
have a critical role at various steps of the virus life cycle.
Inhibitors of virus-cell attachment and fusion, reverse
transcription, protease-mediated maturation cleavage of
viral protein precursors, and provirus integration into
the host-cell genome, can be administered in multiple
types of associations to minimize the emergence of
resistance in highly active antiretroviral therapies
(HAART). Among all the antiretroviral molecules, anti-
bodies occupy a special position as they can inhibit
HIV-1 replication by interfering with multiple steps of
virus-cell interaction. Extracellular antibodies can neu-
tralize HIV-1 at the early phase of cell attachment or
entry of the virus [1]. On the other hand, intracellular
antibodies (or intrabodies) can block virus replication by
interfering with different processes, such as intracellular
trafficking of incoming virions or assembly and egress of
the virus progeny. The design of virus-resistant cells via
intracellular expression of specific single chain fragment
variable (scFv) antibodies directed to the virus has been
successfully used to block HIV-1 replication in vitro
[2-4]. The viral proteins which have been targeted by
these intrabodies include structural proteins, such as the
envelope glycoprotein gp120 [5] or the matrix protein
MAp17 [6], the viral enzyme reverse transcriptase [7],
and the auxiliary proteins Tat [8,9] and Vif [10,11].
The baculovirus (BV) Autographa californica multiple
nucleopolyhedrovirus (AcMNPV) is an insect virus with
a large double-stranded DNA genome packaged in a
membrane-enveloped, rod-shaped protein capsid [12].
BVs have been extensively used over two decades as
expression vectors for the production of recombinant
proteins in insect cells [13]. The current interest of BVs
resides in their promiscuous nature as gene transfer vec-
tors, capable of transducing a large repertoire of estab-
lished and primary cells, of both mammalian and
nonmammalian origins [14,15]. Recombinant BVs carry-
ing nonviral glycoproteins fused or nonfused to their
own envelope glycoprotein GP64 have been advanta-
geously used in the baculovirus-display technology and
its multiple biological and therapeutic applications
[16,17]. For example, fusion of scFv specific for the car-
cinoembryonic antigen (CEA) to GP64 conferred to the
BV vector displaying scFv-CEA a targeting and binding
specificity to CEA-expressing cells [18,19]. However, the
fusion to GP64 restricts the display to the poles of the
virions as well as the number of copies of fusion pro-
teins, and other strategies using fusion to VSV-G glyco-
protein have therefore been proposed [16,17,20,21].
It has been shown that the intracellular expression
of a scFv derived from a monoclonal antibody
(MH-SVM33) directed to a highly conserved C-term-
inal epitope of the HIV-1 MAp17 domain [22,23],
scFv/p17, resulted in an efficient antiviral effect, as
determined using CAp24-based ELISA and reverse
transcription assays [6]. The MH-SVM33 epitope was
localised near the MAp17-CAp24 junction and has
been found to be accessible on recombinant Gag
precursor (Pr55Gag), as shown by the high level
of immunoreactivity of virus-like particles (VLP)
produced in Sf9 cells and analyzed in situ by immuno-
electron microscopy [24]. However, the exact molecu-
lar mechanism of the scFv/p17-mediated inhibitory
activity has yet to be determined, since the MAp17
protein is involved in multiple viral functions within
the infected cell (reviewed in [25]).
The original goal of our study was to try and elucidate
the mechanism of the scFv/p17-mediated inhibitory
activity, and its potential use for diagnostic or therapeu-
tic applications. Insect cells infected by AcMNPV
expressing Pr55Gag (AcMNPV-Pr55Gag) have been
shown to produce vast amounts of VLP mimicking
immature virions [26]. AcMNPV-Pr55Gag-infected Sf9
cells represent a convenient model for studying HIV-1
assembly [24,27-32], coencapsidation of Gag and partner
proteins [33-35], and Gag processing by viral protease
coexpressed in trans [36,37]. We constructed two
recombinant BVs expressing scFv/p17 in two different
formats. The N-myristoylation-competent version
scFvG2/p17 carried a sequence which started with the
N-terminal dipeptide Met-Gly, while the N-myristoyla-
tion-incompetent version scFvE2/p17 started with Met-
Glu. Both scFV were incapable of blocking the assembly
of VLP, or be copackaged with Pr55Gag into VLP. How-
ever, we found that scFvE2/p17 was incorporated into
the baculoviral envelope (BV-E2/p17), and retained its
anti-MAp17 functionality when displayed at the surface
of BV particles. BV-E2/p17 represented therefore a
potential biological tool for depletion of soluble MAp17
protein, or/and for competition with HIV-1 MAp17
receptors in in vitro or ex vivo experiments [25]. Inter-
estingly, we found that another scFv molecule, referred
to as scFv-M6-1B9 [38,39] and directed towards CD147
(also known as M6, OK, 5F7, TCSF, Basigin or EMM-
PRIN), was also displayed at the surface of baculoviral
particles when fused to the same N-terminal octadeca-
peptide sequence from scFvE2/p17, abbreviated N18E2.
This suggested that the N-terminal octadecapeptide
sequence N18E2 carried the BV envelope addressing
function and acted as a signal peptide for BV display.
The fusion of this octadecapeptide sequence to the
N-terminus of scFv molecules of biological interest
could be used as a general strategy for BV-display, and
as an alternative to fusion to GP64 or VSV-G.
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Insect cells and baculovirus infection
Spodoptera frugiperda Sf9 cells were maintained as
monolayers at 28°C in Grace’si n s e c tm e d i u ms u p p l e -
mented with 10% fetal bovine serum (FBS, Sigma),
penicillin (200 U/ml), and streptomycin (200 μg/ml;
Gibco-Invitrogen). They were infected with one, or coin-
fected with two or more recombinant BVs simulta-
neously at a multiplicity of infection (MOI) ranging
from 2.5 to 20 pfu/cell, as previously described [24,28].
Construction of scFv against HIV-1 MAp17 and CD147
The hybridoma cell line MH-SVM33C9/ATCC HB-8975
was obtained from the American Type Culture Collection
(ATCC, Manassas, VA). The monoclonal antibody
MH-SVM33 reacts with the conserved epitope
121DTGHSSQVSQNY
132 at the C-terminus of the matrix
protein (MAp17) of HIV-1 [22,23]. Total RNA was
extracted from hybridoma cells using the RNeasy Mini kit
(Qiagen Inc., Hilden, Germany), and the first strand of
cDNA was synthesized using the oligodT-18 primer of the
Transcriptor High Fidelity cDNA synthesis kit (Roche,
Mannheim, Germany). The variable regions (V) of heavy
(VH) and light chains (VL) were then amplified from
cDNA using specific forward (Fw) and reverse (Rev)
primers. Fw-VHP17 (5’-ATATGCTAGCGGCCCA-
GGCGGCCCAGATCCAGTTGGTGCAGT-3’)a n dR e v -
VHP17 (5’-CGACCCTCCACCGCGGACCCGCCACCTC-
CAGACCCTCCGCCACCTGCA GAGACAGTGACCA-
GAGTCCC-3’)w e r eu s e df o rt h eV H fragment, and
Fw-VLP17 (5’-GGGTCCGGCGGTGGAGGGTCGGATG-
TTGTGATGACCCAGACTCCA-3’)a n dR e v - V LP17
(5’-ATATAAGCTTTCATTAAGCGTAGTCCGGAACG-
TCGTACGGGTACTGGCCGCCCTGGCCTT
TGATTTCCAGC-3’)f o rt h eV L fragment. The fragment
encoding the single-chain antibody to MAp17 (scFv/p17)
was constructed by overlapping PCR using Fw-VHP17 and
Rev-VLP17 primers, both containing a Sfi Is i t e( s h o w n
underlined). The construction and characterization of
HA-tagged scFv M6-1B9 directed against CD147 have
been described in a previous study [38,39].
Recombinant BV
Foreign genes were inserted into the genome of
AcMNPV, under the control of a chimeric AcMNPV-
Galleria mellonella MNPV polyhedrin promoter in
the case of recombinant HIV-1 Gag polyproteins
[24,28,29,31,32], or under the control of the AcMNPV
polyhedrin promoter in the case of pBlueBac4.5-derived
vectors. AcMNPV-Pr55Gag, which expressed the
N-myristoylated full-length Gag polyprotein (Pr55Gag) of
HIV-1, has been described in detail in previous studies
[30-32,36,40]. The recombinant AcMNPV expressing
CAR (BV
CAR), the high affinity receptor for Coxsackie B
and Adenovirus, has been described and characterized in
a previous study [41]. BV
CAR virions have been shown to
display the CAR glycoprotein at their surface [41]. A
DNA fragment coding for H6MA-CA, a non-N-myristoy-
lated, carboxyterminal-truncated version of HIV-1 Gag
polyprotein containing the matrix (MA) and capsid (CA)
domains with an oligo-histidine (H6) tag at its N-termi-
nus, was generating using the following pairs of primers:
the first pair consisted of Fw primers 5’-CTAG-
CATGGGTGCGAGAG-3’ and 5’-CATGGGTGCGA-
GAGCG-3’ and the second pair consisted of Rev primers
5’-CTTACTACAAAACTCTTGCTTTATG-3’ and 5’-
GTACCTTACTAC AAAACTCTTGC-3’.T w oP C R
reactions were performed using the HIV-1 plasmid
pNL4-3 as the template. The PCR products from both
reactions were then mixed, denatured, and hybridized to
obtain DNA fragments with Nhe Ia n dKpn Ic o h e s i v e
ends, competent for ligation to pBlueBac4.5-His inter-
mediate vector linearized with Nhe Ia n dKpn I. Plasmid
pBlueBac4.5-His was derived from pBlueBac4.5 (Invitro-
gen, San Diego, CA) by insertion of a sequence coding
for the (H6)t a ga n daG S G S A Sl i n k e ru p s t r e a mt ot h e
Nhe I site. Sf9 cells were cotransfected with pBlueBac4.5-
H6MA-CA and linearised BV DNA (Bac-N-Blue™ Trans-
fection kit; Invitrogen). Positive Sf9 cells harboring
recombinant BVs were isolated using the blue plaque
selection method after beta-galactosidase staining.
Recombinant BV, abbreviated BV-H6MA-CA, was iso-
lated using the blue plaque selection method as above.
Recombinant H6MA-CA protein was produced in Sf9
cells infected with BV-H6MA-CA. Sf9 cells were har-
vested at 48 h post infection (pi), and H6MA-CA protein
recovered from clarified Sf9 cell lysate by affinity chro-
matography on Ni
2+-NTA-agarose column (Qiagen, Hil-
den, Germany), as previously described [42]. Protein
concentration in H6MA-CA samples was determined by
Bradford protein assay (Pierce; Thermo Fisher Scientific
Inc., Rockford, IL, USA). Recombinant H6MA-CA pro-
tein was used as the antigenic substrate for scFvG2/p17
and scFvE2/p17 in ELISA and co-immunoprecipitation
experiments.
The DNA fragment encoding scFv/p17, obtained as
described above, was cloned into the Nhe I and Hind III
sites of the pBlueBac4.5 plasmid. The 5’ and 3’ ends of
scFv/p17 fragment in the pBlueBac-scFv/p17 vector
were then modified by oligonucleotide insertion at both
Nhe Ia n dHind III sites, to obtain two versions of the
scFv/p17 cDNA. One encoded the dipeptide Met-Gly at
the N-terminus of scFv/p17, generating the scFvG2/p17
clone, the other the dipeptide Met-Glu, generating the
scFvE2/p17 clone. At the 3’ end of both clones, we
inserted an oligonucleotidee n c o d i n gt h eI n f l u e n z aA
virus hemagglutinin epitope YPYDVPDYA (HA tag). Sf9
cells were then cotransfected with the resulting plasmid
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BV DNA. Recombinant BVs were isolated using the
blue plaque selection method, as described above
The DNA fragment for the HA-tagged scFv M6-1B9
was amplified using plasmid pComb3X-scFv-M6-1B9 as
the template [39], with the M6-1B9 Fw primer (5’-
GAGGAGGAGCTGGCCCAGGCGGCCCAGATCCAG-
TTGGTGCAGTCTGGAGAGCTAGTGATGACCCA-
GACTCCAGC-3’) encoding the N-terminal 18 amino
a c i d so fs c F v E 2 / p 1 7(
1MEASLAAQAAQIQLVQSG
18),
and the M6-1B9 Rev primer (5’-CTCCTCCTC-
GGCCGCCCTGGCCACTAGTGACAGATGGGGCTG-
3’). The scFv-M6-1B9 was then cloned into the Sfi Is i t e
of Sfi I-restricted pBlueBac-scFvE2. The recombinant
BV was isolated as described above, and abbreviated
BV-N18E2/M6.
Isolation of BV particles
Concentrated stocks of recombinant BV expressing
scFv/p17 molecules, BV-scFvG2/p17 and BV-scFvE2/
p17, respectively, were prepared as follows [41]. Infected
Sf9 cell culture supernatants were harvested at 50 to 60
h post infection (pi), and clarified by centrifugation at
2,400 rpm and 4°C for 10 min. Aliquots (11-ml) of clari-
fied culture supernatant were subjected to ultracentrifu-
gation at 28,000 rpm for 1 h at 4°C through a 1-ml
sucrose cushion (20% sucrose, w:v in PBS) in Beckman
SW41 rotor. Each baculoviral pellet was resuspended by
gentle shaking in sterile phosphate-buffered saline (PBS)
o v e r n i g h ta t4 ° C( 1 0 0μl per centrifuge tube). The titers
of BV suspensions ranged usually between 5 × 10
9 and
1×1 0
10 pfu/ml, as determined by plaque titration in
Sf9 cells (pfu/ml), which corresponded to 1 × 10
12 to
5×1 0
12 BV physical particles per ml [12,41]. When
needed, e.g. for electron microscopy, BV particles were
further purified by isopycnic ultracentrifugation in linear
sucrose-D2O gradient [35,40]. Gradients (10-ml total
volume, 30-50%, w:v) were generated from a 50%
sucrose solution made in D2O buffered to pH 7.2 with
N a O H ,a n da3 0 %s u c r o s es o l u t i o nm a d ei n1 0m M
Tris-HCl, pH 7.2, 150 mM NaCl, 5.7 mM Na2EDTA.
The gradients were centrifuged for 18 h at 28,000 rpm
in a Beckman SW41 rotor. 0.5 ml-fractions were
collected from the top, and proteins analyzed by
SDS-PAGE and Western blotting with the required anti-
bodies. BV particles were recovered in fractions with an
apparent density ranging from 1.08 to 1.15.
Cell fractionation and scFv purification
BV-infected Sf9 cells were harvested between 48 and
72 h pi. After cell lysis, cellular fractionation was
performed using the FractionPREP™ Cell Fractionation
System (Medical & Biological Laboratories Co. Ltd.,
Nagoya, Japan). Four subcellular protein fractions were
thus obtained, cytosol, nucleus, membrane/particulate
and cytoskeletal fractions. The scFvE2/p17 protein was
purified by affinity selection on anti-HA tag antibody
Affimatrix gel (Roche Applied Science, IN, USA), follow-
ing the manufacturer’s instructions. Each fraction eluted
from the affinity gel, using elution buffer containing HA
peptide (Roche Applied Science) as binding competitor
to displace the bound proteins, was analyzed by
SDS-PAGE, and scFvG2/p17 or scFvE2/p17 detected by
Western blotting, using anti-HA tag antibody, as
described below.
Gel electrophoresis, membrane transfer and antibodies
Polyacrylamide gel electrophoresis of SDS-denatured
protein samples (SDS-PAGE), and immunoblotting ana-
lysis have been described in detail in previous studies
[34,35,40]. Briefly, proteins were electrophoresed in
SDS-denaturing, 10%-polyacrylamide gel and electrically
transferred to nitrocellulose membrane (Hybond™-C-
extra; Amersham Biosciences). Blots were blocked in 5%
skimmed milk in Tris-buffered saline (TBS) containing
0.05% Tween-20 (TBS-T), rinsed in TBS-T, then succes-
sively incubated with mouse monoclonal antibody to
Influenza A virus hemagglutinin epitope YPYDVPDYA
(HA tag antibody; Sigma, St Louis, MO, USA), or pri-
mary rabbit anti-Gag antibody, followed by relevant
anti-IgG secondary antibodies, at working dilutions ran-
ging from 1:1,000 to 1:10,000. Anti-HIV-1 Gag rabbit
polyclonal antibody (laboratory-made; [35]) was raised
in rabbit by injection of bacterially-expressed, GST-
fused and affinity-purified carboxyterminally truncated
Gag protein consisting of the full-length MA domain
and the first seventy-eight residues of the CA domain
(Pst Is i t e ;gagLai sequence). Monoclonal antibody
against baculoviral envelope GP64 glycoprotein, clone
AcV1 was purchased from Santa Cruz Biotechnology
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
Apparent molecular weights were estimated by compari-
son with prestained protein markers (Precison Plus Pro-
tein™ Standards, Dual Color; BioRad Laboratories, Inc.,
Bio-Rad France). For protein quantification, blots were
scanned and protein bands were quantitated by densito-
metry, using the VersaDoc image analyzer and the
Quantity One program (BioRad).
Indirect ELISA
The functionality of recombinant scFv/p17 was evalu-
ated by their binding activity to the synthetic MAp17
peptide
121DTGHSSQVSQNY
132 (GenScript; Piscataway,
USA) and H6MA-CA protein prepared as above, in stan-
dard indirect ELISA procedure. In brief, aliquots
(100 μl) of MA p17 peptide solution at 50 μg/ml, or of
H6MA-CA protein solution at 5 μg/ml in coating buffer
(0.1 M NaHCO3, pH 9.6) were incubated overnight at
Kitidee et al. BMC Biotechnology 2010, 10:80
http://www.biomedcentral.com/1472-6750/10/80
Page 4 of 214°C in 96-well microtiter plates (NUNC, Roskilde,
Denmark). The coated wells were blocked with 200 μl
of blocking buffer (2% bovine serum albumin in TBS;
T B S - B S A )f o r1ha tr o o mt e m p e r a t u r e( R T ) ,t h e n
washed five times with washing buffer (0.05% Tween-20
in TBS; TBS-T). Aliquots (100 μl) from clarified cellular
lysates of BV-G2/p17- or BV-E2/p17-infected Sf9 cells
in blocking buffer was added to each well and incuba-
tion proceeded for 1 hr at RT. After five cycles of wash-
ing with TBS-T, monoclonal anti-HA tag antibody
(Sigma) was added at dilution 1:2,500 in TBS-BSA, and
incubated for 1 hr at RT. After extensive washing with
TBS-T, the reaction was developed by addition of 100 μl
p-nitrophenylphosphate substrate (Sigma), and OD mea-
sured at 405 nm using an ELISA plate reader at the
optimum time. The antigen-binding activity of scFv-M6-
1B9 and chimeric scFvE2/M6-1B9 was assessed in
ELISA using immobilized recombinant CD147-biotin
carboxyl carrier protein (BCCP) fusion protein as the
antigen, produced as previously described [39].
Competition ELISA
Microtiter plates (NUNC) were coated with 50 μlo f1 0
μg/ml of avidin in coating buffer (0.1 M NaHCO3, pH
6 . 8 )a n di n c u b a t e do v e r n i g h ta t4 ° Ci nm o i s tc h a m b e r .
The coated wells were then blocked with 200 μlo f
blocking buffer (2% BSA in TBS) for 1 h at RT, then
washed four times with washing buffer (0.05% Tween-20
in TBS). 50 μl-aliquots of 50 μg/ml of biotinylated-
peptide 17.1 (Bp17.1) in blocking buffer were added to
each well and incubated for 1 h at RT. In parallel,
scFvE2/p17 purified by anti-HA tag affinity as described
above was mixed with p17 peptide at the final peptide
concentration of 1 μg/ml, and incubated for 1 h at RT.
After washing the wells, the mixture was added to the
wells and incubated for 1 h at RT. Bound scFvE2/p17
was monitored by adding 50 μl of HRP-conjugated
monoclonal anti-HA tag antibody (Sigma) at dilution
1:1,000 in blocking buffer. The wells were washed four
times prior to the addition of 50 μlo f3 , 3 ’,5,5’-tetra-
methyl-benzidine (TMB) substrate. Reaction was
stopped by addition of 50 μlo f1NH C l ,a n do p t i c a l
densities (OD) at 450 nm were measured using an
ELISA plate reader. The percentage of inhibition (PI)
was given by the following formula: PI = 100-[(B:Bo) ×
100], where B and Bo were the OD values for scFvE2/
p17 with and without inhibitor, respectively.
Co-immunoprecipitation
Sf9 cells co-infected with BV-E2/p17 (or BV-G2/p17)
and BV-H6MA-CA were harvested by centrifugation at
5,000 rpm for 10 min at 4°C. The cell pellets were
washed 3 times with cold TBS, then resuspended in
lysis buffer (1% Brij-35 in TBS) and incubated on ice for
45 min. The cell lysates were clarified by centrifugation
at 13,000 rpm for 1 h at 4°C, and supernatants added to
pre-washed anti-HA tag affinity gel. After incubation
overnight at 4°C with gentle shaking, the resin was
washed 3 times with washing buffer (20 mM Tris,
pH7.5, 0.1 M NaCl, 0.1 mM EDTA, 0.05% Tween20).
Immunocaptured proteins were eluted from the affinity
gel by heating in SDS-containing buffer (20 mM Tris
pH 7,5, 2 mM EDTA, 5% SDS, 20% glycerol, 200 mM
DTT, 0.02% bromophenol blue) at 100°C for 5 min. The
resin was pelleted by centrifugation and the supernatant
analyzed by SDS-PAGE and Western blotting, using
anti-His6 tag and anti-HA tag primary antibodies, both
purchased from Sigma.
Immunofluorescence (IF) microscopy
BV-infected Sf9 cell monolayers were harvested at 48 h
pi, fixed with 3% paraformaldehyde in phosphate buf-
fered saline (PBS) and permeabilized in 0.2% (v/v) Tri-
ton X-100 in PBS. Cells were blocked with 3% BSA in
PBS (PBS-BSA), and HA-tagged scFv/p17 detected by
reaction with mAb anti-HA (1:10,000 in PBS-BSA) and
Alexa Fluor® 488-labeled goat anti-mouse IgG antibody
(Molecular Probes, Invitrogen). For double labeling of
scFv/p17 and Gag proteins, cell samples were reacted
with rabbit anti-Gag antibody (1:1,000 in PBS-BSA) and
Alexa Fluor® 546-labeled goat anti-rabbit IgG (Molecular
Probes, Invitrogen). Samples were treated with DAPI
and mounted on slides. For conventional IF microscopy,
images were acquired using an Axiovert 135 inverted
microscope (Zeiss) equiped with an AxioCam video
camera. For confocal microscopy, samples were analyzed
using a Leica TCS SP2 confocal microscope.
Flow cytometry
ScFv-expressing Sf9 cells were resuspended in 200 μl
PBS and incubated with monoclonal anti-HA tag anti-
body for 1 h at room temperature (RT), and at the dilu-
tion recommended by the manufacturer (Sigma), then
pelleted. The cell pellet was resuspended in 200 μlP B S
and reacted with Alexa Fluor® 488-labeled goat anti-
mouse IgG antibody (Molecular Probes, Invitrogen).
The cell suspension was then diluted with 10 volumes
of PBS, and analyzed by flow cytometry using a BD
FACSCanto™ II cytometer (Becton Dickinson Bios-
ciences). At least 10,000 events were acquired for each
experiment using the DIVA 6 software (Becton
Dickinson).
Electron microscopy (EM)
Specimens were processed for EM and observed as
previously described [41]. In brief, pelleted virions of
BV-E2/p17 and BV-G2/p17 were resuspended in 20 μl-
aliquots of 0.14 M NaCl, 0.05 M Tris-HCl buffer, pH
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brane on nickel grids. The grids were incubated with
primary antibody (anti-HA tag monoclonal antibody) at
a dilution of 1: 50 in TBS for 1 h at room temperature
(RT). After rinsing with TBS, the grids were post-incu-
bated with 20-nm colloidal gold-tagged goat anti-mouse
IgG antibody (British Biocell International Ltd, Cardiff,
UK; diluted to 1: 50 in TBS) for 30 min at RT. After
rinsing with TBS, the specimens were negatively stained
with 1% uranyl acetate in H20f o r1m i na tR T ,r i n s e d
again with TBS, and examined under a JEM 1400 Jeol
electron microscope equiped with an Orius-Gatan digi-
talized camera (Gatan France, 78113 Grandchamp).
Statistics
Results were expressed as mean ± SEM. of n observa-
tions. Sets of data were compared with an analysis of
variance (ANOVA) or a Student’s t test. Differences
were considered statistically significant when P < 0.05.
Symbols used in figures were (*) for P < 0.05, (**) for
P < 0.01, (***) for P < 0.001, and ns for no significant
difference, respectively. All statistical tests were per-
formed using GraphPad Prism version 4.0 for Windows
(Graphpad Software).
Results
Expression and characterization of scFvG2/p17 and
scFvE2/p17 molecules in recombinant BV-infected
Sf9 cells
The monoclonal antibody secreted by the MH-SVM33C9
hybridoma cell line reacts with the highly conserved and
accessible epitope
121DTGHSSQVSQNY
132 correspond-
ing to the C-terminus of HIV-1 MAp17 [22-24]. A single
chain antibody derived from MH-SVM33 (scFv/p17) and
expressed intracellularly showed an inhibitory effect on
HIV-1 replication and virus release [6]. We generated
two scFv/p17 subclones from the MH-SVM33C9 hybri-
doma cell line, scFvE2/p17 and scFvG2/p17, of which the
full sequence could be communicated upon request. The
N-terminal octadecapeptide sequence in scFvE2/p17 read
1MEASLAAQAAQIQLVQSG
18 ,a n d
1MGLAAQAA-
QIQLVQSGPE
18 in scFvG2/p17. Both subclones were
also modified at the C-terminus by the addition of a HA-
tag, the Influenza A virus hemagglutinin epitope
YPYDVPDYA, and when inserted into the baculoviral
genome, generated two recombinant BVs, BV-E2/p17
and BV-G2/p17, respectively. The rationale for the
N-terminal modification was that the dipeptide Met-Gly
at the N-terminus of scFvG2/p17 represented a N-myris-
toylation signal which would promote the addressing
scFvG2/p17 to the same compartment as the N-myris-
toylated MAp17 protein and Pr55Gag polyprotein. We
have shown in previous studies that the Met-Gly signal
was functional in insect cells in terms of recognition by
N-myristoyl transferase, and that N-myristoylated glycine
residue at the N-terminus of Pr55Gag is a prerequisite
for plasma membrane addressing of unprocessed
Pr55Gag, and budding and egress of membrane-envel-
oped VLP from Sf9 cells [24,27-36,40].
Sf9 cells infected with BV-G2/p17 or BV-E2/p17 were
harvested at 24, 48 and 72 h post infection (pi), lysed in
hypotonic buffer, and the kinetics of synthesis of
scFvG2/p17 and scFvE2/p17 was analyzed by SDS-
PAGE and Western blotting using anti-HA tag antibody.
The extracellular culture medium was analyzed in paral-
lel. We found that scFvE2/p17 protein (migrating with
an apparent molecular mass of 30 kDa) was detectable
as early as 24 h, and was maximal at 72 h pi. In con-
trast, scFvG2/p17 was detected at later times (48 h pi),
and in 4- to 5-fold lower amounts, compared to scFvE2/
p17 at 48-72 h pi (Figure 1a). However, both scFvE2/
p17 and scFvG2/p17 proteins were stable over a period
of 72 h, with no major breakdown products detected in
the Western blot patterns.
Cell lysates were then clarified by centrifugation, and
scFvG2/p17 and scFvE2/p17 were probed in soluble
fraction (S) and insoluble pellet (P), respectively. We
found that 15-20% of the whole recombinant scFvE2/
p17 protein synthesized was recovered as soluble mate-
rial, as determined by scanning and densitometric analy-
sis of the protein bands on blots, with a maximum at
48 h pi (Figure 1b; leftmost half of the panel). The pro-
portion of soluble scFvG2/p17 was lower (Figure 1b;
rightmost half), with only 8-10% of scFvG2/p17 protein
recovered in the soluble fraction. The difference in the
intracellular levels of the two recombinant proteins
could not be explained by a higher level of scFvG2/p17
secretion, compared to scFvE2/p17, as no scFvG2/p17
protein was detected in the culture medium at any time
pi. Only scFvE2/p17 protein was detectable in the extra-
cellular medium, as described below.
Cellular distribution of scFvG2/p17 and scFvE2/p17 in
recombinant BV-infected Sf9 cells
We next performed cell fractionation to determine in
which subcellular compartments the majority of scFvE2/
p17 and scFvG2/p17 proteins were localized. Of note,
the distinction between cytosol (Cy), membranes and
organelles (Mb), nucleus (Nu) and cytoskeleton (Sk) was
only operational, and did not preclude probable cross
contaminations between different fractions. With this
restriction in mind, scFvE2/p17 was found to be asso-
ciated with the cytosolic fraction and nuclear pellet in
similar amounts (ca. 20-25% each), but larger quantities
(50-60%) were recovered in the insoluble fraction of
cytoskeletal proteins (Figure 1c; leftmost half of the
panel). Only small amounts of scFvE2/p17 were detected
in the membrane fraction (Figure 1c, Mb lane). The
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Figure 1 Expression, solubility and cellular localization of scFvE2/p17 and scFvG2/p17 in Sf9 cells. (a), Level of expression. Sf9 cells were
mock-infected (lanes mo), or infected with BV-E2/p17 or BV-G2/p17, and harvested at 24, 48 and 72 h pi, as indicated on top of the panel.
Whole cell lysates were analyzed by SDS-PAGE and Western blotting using anti-HA tag antibody. (b), Solubility. Lysates of mock-infected cells
(mo) or BV-E2/p17- or BV-G2/p17-infected cells harvested at 24, 48 and 72 h pi, as indicated on top of the panel were clarified by centrifugation,
and soluble fraction (S) and pelletable material (P) analyzed as above. M, molecular mass markers, with their apparent molecular masses
indicated in kilodaltons (kDa) on the right side of the blots. (c), Cell fractionation. Sf9 cells infected with BV-E2/p17 or BV-G2/p17 as indicated
on top of the panel were harvested at 48 h pi and processed for cell fractionation into cytosolic compartment (Cy), membranes (Mb), nuclear
compartment (Nu) and cytoskeletal-associated proteins (Sk). Subcellular fractions were analyzed by SDS-PAGE and Western blotting using anti-HA
tag antibody.
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scFvG2/p17 protein, which was undetectable in the
cytosolic and nuclear fractions, but distributed
unequally between membrane and cytoskeletal frac-
tions, two-thirds and one-third of the total, respec-
tively (Figure 1c, rightmost half of the panel). Thus,
the N-terminal G
2 mutation conferred two new prop-
erties to scFvG2/p17, compared to its scFvG2/p17
counterpart, (i) a lower level of expression, and (ii) a
relocation to and strong association with the membra-
nal fraction. The membrane association of scFvG2/p17
determined by cell fractionation was ap r i o r iconsistent
with the membrane targeting expected for a N-myris-
toylated protein.
Cellular localization of scFvG2/p17 and scFvE2/p17
was then studied in situ. BV-infected Sf9 cells were har-
vested at 48 h pi and examined in immunofluorescence
(IF) microscopy or analyzed by flow cytometry using
anti-HA tag antibody, with or without membrane per-
meabilization with detergent. Fluorescent signal of
scFvE2/p17 was detected in both nonpermeabilized
(Figure 2A, i) and Triton X100-permeabilized cells
(Figure 2A, ii), whereas scFvG2/p17 fluorescence was
only detectable in permeabilized cells (not shown). Flow
cytometry of HA tag-positive cells confirmed the acces-
sibility of scFvE2/p17 at the surface of nonpermeabilized
cells, and the absence of significant amounts of scFvG2/
p17 molecules at the cell surface (Figure 2B). Considering
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Figure 2 In situ analysis of scFvE2/p17 and scFvG2/p17 proteins in Sf9 cells. (A), Immunofluorescence (IF) microscopy. Sf9 cells expressing
scFvE2/p17 alone (i, ii), or coexpressing scFvE2/p17 and Pr55Gag (iii), were harvested at 48 h pi and nonpermeabilized (i), or permeabilized with
Triton X-100 (ii, iii). Cells were reacted with anti-HA tag monoclonal antibody followed by Alexa Fluor® 488-labeled complementary antibody.
(B), Flow cytometry. Nonpermeabilized Sf9 cells expressing scFvE2/p17, scFvG2/p17 or the scFv-N18E2/M6 chimera were harvested at 48 h pi,
reacted with antibodies as in (A), and analyzed by flow cytometry. Results shown were the proportion of HA tag-positive cells, expressed as the
fold ratio over the values of control cells, attributed the value of 1. Control consisted of BV
CAR-infected cells, i.e. cells expressing irrelevant
membrane glycoprotein. BV
CAR was a recombinant BV expressing the human CAR glycoprotein, and BV
CAR-infected cells released CAR-displaying
virions in the extracellular medium [41]. Average of three separate experiments, m ± SEM; (**), P < 0.01; ns, not significant.
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tion upon cell fractionation (refer to Figure 1c), the
results of IF microcopy and flow cytometry suggested
that the majority of scFvE2/p17 molecules were
addressed to the plasma membrane and highly accessible
at the cell surface, but proned to dissociate from the
membrane upon cell disruption and fractionation, and to
relocate into the soluble fraction. In contrast, we
observed a major intracellular retention of most of the
scFvG2/p17 molecules. Together with the data of cell
fractionation (Figure 1c), this suggested that scFvG2/p17
protein was in majority sequestered in the intracellular
membrane network.
When Sf9 cells were coinfected with two recombinant
BVs to coexpress scFvE2/p17 and N-myristoylated
Pr55Gag, we detected no significant change in the IF
pattern of scFvE2/p17, compared to single infected cells
expressing scFvE2/p17 alone (Figure 2A, compare panels
ii and iii). This suggested that there was no major cellu-
lar redistribution of the scFvE2/p17 molecules in the
presence of the Gag precursor. Similarly, no cellular
redistribution of scFvG2/p17 was observed when coex-
pressed with Pr55Gag (not shown).
Immunological characterization of extracellular scFvE2/
p17 molecules: functionality and specificity
(i) Antigen recognition by scFvE2/p17 in vitro
Since a significant proportion of scFvE2/p17 molecules
occurred as soluble intrabody in the cytosolic fraction,
we tested lysates of BV-E2/p17-infected Sf9 cells for the
antigen binding activity of scFvE2/p17 in ELISA. Two
types of immobilized antigens were used: a synthetic
peptide p17.1, which reproduced the epitope sequence
from HIV-1LAI MAp17 (
121DTGHSSQVSQNY
132), and
corresponded to the immunogen used to generate MH-
SVM33; a recombinant H6MA-CA protein of 39 kDa,
which carried the same epitope as p17.9 (Table 1), but
was embedded in the Gag polyprotein. The binding data
from ELISA clearly showed that recombinant scFvE2/
p17 reacted with its specific epitope in both configura-
tions (Figure 3a, b), and in a dose-dependent manner
(Figure 3c). Competition ELISA indicated that scFvE2/
p17 bound to its epitope with a higher affinity when it
was used as free p17.1 peptide, compared to the H6MA-
CA polyprotein used at equivalent epitope molarities
(Figure 4a), suggesting that scFvE2/p17 preferentially
bound to cleaved matrix protein MAp17, compared to
non processed Gag precursor.
(ii) HIV-1 strain-specificity of antigen recognition by scFvE2/
p17 and scFvG2/p17
Although the MAp17 epitope recognized by the mono-
clonal antibody MH-SVM33 is highly conserved among
HIV-1 strains, there are some subtle differences in
amino acid sequence. To assess the stringency of
scFvE2/p17 towards HIV-1 MAp17 variants, we tested
five different MAp17 peptides versus the original pep-
tide epitope p17.1 in competition ELISA (Table 1). All
MAp17 peptide variants competed with p17.1 to signifi-
cant levels, considering that control homologous compe-
tition (bound p17.1 vs free p17.1) showed a 90% binding
inhibition (Figure 4a, and Table 1). The lowest competi-
tion was observed for peptide p17.7, which corre-
sponded to the MAp17 epitope of isolate g22s2, a
molecular clone of HIV-1 isolated from HAART treated
AIDS patients [43]. The difference between p17.7 and
p17.1 corresponded to an Ala-Val mutation at position
128 in the MA domain. Valine carries a bulkier and
more sterically hindered side chain, compared to
alanine, and many examples have been reported in the
literature of highly deleterious effects provoked by Ala-
to-Val substitutions, in terms of protein conformation
and function [44,45]. Competition ELISA was also
performed using p17.1 versus a synthetic peptide
of identical composition but of inverted sequence,
YNQSVQSSHGTD. No competition was observed
(Table 1), implying that N-to-C orientation of the pep-
tide sequence and the C-terminal position of tyrosine
residue-132 were crucial for the recognition of the epi-
tope by scFvE2/p17.
The affinity and binding specificity of scFvG2/p17 to
the different MAp17 peptides was also tested using
competition ELISA, as above. Since only a minor frac-
tion of recombinant scFvG2/p17 protein was recovered
in the soluble cytosolic fraction, clarified lysates of cells
Table 1 Affinity of scFvE2/p17 for different variants of
the conserved C-terminal epitope of HIV-1 MAp17
(a)
Competitor Epitope Binding
competition
vs p17.1 (%)
Origin or
HIV-1
isolate
Unrelated
antigen
(negative
control)
CD147 (M6) 5.2 ± 2.9 -
17.1
(positive control)
DTGHSSQVSQNY 89.5 ± 1.6 LAI
(b)
17.3 DTGHSSQISQNY 74.7 ± 10.2 1M-1005
(c)
17.7 DTGHSSQASQNY 44.0 ± 18.0 g22s2
(d)
17.8 DTGHSKQVSQNY 81.5 ± 9.5 4
(e)
17.9 DTGNNSQVSQNY 68.8 ± 2.2 pNL4.3
(f)
Inverted p17.1 YNQSVQSSHGTD 3.8 ± 1.5 -
(a) Competition for scFvE2/p17 binding between the dodecapeptide p17.1
(corresponding to residues 121-132 in the MAp17 from HIV-1LAI, used as
immunogen) and other epitope variants was determined by ELISA, as
examplified in Figure 4c. Data presented are m ± SEM (n = 3). Residues
differing from the LAI prototype sequence are in bold.
(b) [63].
(c) [64].
(d) [43].
(e) [65].
(f) [66].
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Figure 3 Functionality of soluble scFvE2/p17: antigen recognition. Sf9 cells were mock-infected or infected with BV
CAR (expressing irrelevant
recombinant protein), or BV-E2/p17, and harvested at 48 h pi. Sf9 cell lysates were clarified by centrifugation, and reacted in ELISA with
immobilized antigen. (a),H 6MA-CA protein; (b, c), synthetic peptide p17.1 (
121DTGHSSQVSQNY
132 epitope). Negative controls were, from left to
right: uncoated well, antigen-coated well without addition of scFvE2/p17-containing lysate, mock-infected cell lysate, and BV
CAR-infected cell
lysate, respectively. (c), Dose-dependent immunoreactivity of scFvE2/p17 towards p17.1 peptide. Soluble scFvE2/p17 from Sf9 cell lysates was
affinity-purified on anti-HA tag antibody-coupled agarose beads. Average of three separate experiments, m ± SEM; (**), P < 0.01; ns, not
significant.
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Figure 4 Immunological characterization of scFvE2/p17: epitope specificity and affinity. (a), Soluble scFvE2/p17 from Sf9 cell lysates was
analyzed in competition ELISA using solid support-adsorbed p17.1 versus soluble p17.1 (homologous, positive control), or versus MAp17 epitope
variants p17.3, p17.7 and p17.9. Negative controls consisted of ELISA in the absence of competing peptide (no competitor), or ELISA in the
presence of irrelevant antigen (CD147), or irrelevant scFv (scFv-M6-1B9). Average of three separate experiments, m ± SEM. (b), Isolation of H6MA-
CA-scFvE2/p17 complexes. Lysates of cells coexpressing H6MA-CA and HA-tagged scFvE2/p17 were separated on affinity matrix consisting of
anti-HA tag antibody-coupled agarose beads, and fractions analyzed by SDS-PAGE and Western blotting, using anti- His6 tag and anti-HA tag
antibodies. Lane 1, whole cell lysate; lane 2, flow-through fraction; lane 3, column wash; lane 4, fraction eluted with SDS-PAGE loading buffer.
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onto anti-HA tag-agarose gel, and specific elution of
scFvG2/p17 protein was carried out using HA peptide-
containing buffer. No significant difference was observed
between scFvG2/p17 and scFvE2/p17 in terms of reac-
tivity with MAp17 epitope variants (Figure 4b). The lack
of difference in the antigen-binding function of soluble
scFvG2/p17 and scFvE2/p17 indicated that the apparent
poorer solubility of scFvG2/p17 compared to scFvE2/
p17 was likely due to its addressing to membranal and
cytoskeletal compartments, and not to major changes in
its overall conformational structure and/or complemen-
tary-determining regions. This underlined the impor-
tance of the N-terminal sequence, which harboured the
only difference between scFvG2/p17 and scFvE2/p17.
Functionality of scFvE2/p17 and scFvG2/p17 as
intrabodies
(i) Antigen binding
Although our recombinant scFvE2/p17 was active
in vitro in ELISA, we sought to determine whether
intracellular scFvE2/p17 molecules could bind in situ to
their MAp17 epitope embedded in Gag polyprotein. Sf9
cells were co-infected with two recombinant BVs, one
expressing scFvE2/p17 (or scFvG2/p17), the other
expressing the non-N-myristoylated Gag polyprotein
substrate H6MA-CA. Possible antigen-intrabody com-
plexes present in cell lysates were isolated by affinity
chromatography on anti-HA tag-agarose gel. The pat-
tern of SDS-PAGE and Western blot analysis showed
that most of the Gag polyprotein H6MA-CA was recov-
ered in the flow-through fraction, and that only a minor
fraction bound to the column as H6MA-CA-scFvE2/p17
complex (Figure 4b, lane 4). This suggested that scFvE2/
p17 intrabody and the non-N-myristoylated H6MA-CA
protein segregated in separate cellular compartments
and that only a small proportion of the scFvE2/p17
molecules could bind to H6MA-CA. This might also
suggest that scFvE2/p17 intrabody had a relatively low
affinity for its Gag-embedded p17 epitope, compared to
fully processed protein MAp17 with accessible p17 epi-
tope at its C-terminus, or free C-terminal p17 peptide.
These different hypotheses are not mutually exclusively.
No detectable antigen-scFv complex was found with
scFvG2/p17 (not shown), which confirmed that the
majority of scFvG2/p17 accumulated in an insoluble
form, and/or in a cellular compartment inaccessible to
cytoplasmic Gag polyprotein.
(ii) Effect of scFvE2/p17 on VLP production
As shown earlier by IF microscopy, Pr55Gag had no sig-
nificant influence on the cellular distribution of scFvE2/
p17 protein (refer to Figure 2 A ,i i i ) .T of u r t h e rs t u d y
the mechanism of HIV-1 antiviral effect of MH-SVM33-
derived scFv/p17 [6], we investigated the possibility that
scFvE2/p17, via its binding to MAp17, could modify the
intracellular trafficking and assembly pathway of
Pr55Gag molecules. Sf9 were co-infected with two
recombinant BVs, one expressing the N-myristoylated
Pr55Gag precursor, the other scFvE2/p17. Pr55Gag
synthesis was analyzed in whole cell lysates, and VLP
production assayed in parallel in the culture medium, as
described in previous studies [34,35,40]. No negative
effect on Pr55Gag protein synthesis and on VLP assem-
b l yw a sd e t e c t e di nt h ep r e s e n c eo fs c F v E 2 / p 1 7( d a t a
not shown). Possible coencapsidation of Pr55Gag and
scFvE2/p17 molecules into VLP during the assembly
process was also investigated. Extracellular VLP were
isolated from the culture medium, and their protein
composition analyzed by SDS-PAGE and Western blot-
ting using anti-Gag and anti-HA tag antibodies: no
scFvE2/p17 was detected in the VLP fraction (not
shown). This was in contrast to the BV particle fraction,
as shown below.
Biophysical status of extracellular scFvE2/p17 protein:
soluble versus particulate
As mentioned above, a significant amount of scFvE2/p17
protein was recovered in the extracellular medium of
BV-E2/p17-infected Sf9 cells. These extracellular
scFvE2/p17 molecules might occur as soluble protein, or
as particle-associated material, e.g. released within mem-
brane microvesicles or exosomes, or associated with cell
debris. In order to determine the status of extracellular
scFvE2/p17 protein, samples from culture mediun were
subjected to isopycnic ultracentrifugation analysis in
sucrose-D2O density gradients [35,40]. Gradient frac-
tions were analyzed by SDS-PAGE and Western blot-
ting, using anti-baculoviral envelope glycoprotein GP64
and anti-HA tag antibodies. We found that the fractions
positive for the C-terminal HA tag of scFvE2/p17 coin-
cided with the anti-GP64-reacting fractions, and corre-
sponded to particulate material sedimenting with the
apparent density of BV particles of the viral progeny, d
= 1.15-1.08 (Figure 5). This suggested that scFvE2/p17
was associated with the BV particles, either coencapsi-
dated with the baculoviral proteins or inserted into the
viral envelope. In the latter case, scFvE2/p17 molecules
could be exposed at the surface of the BV particles with
their active site accessible for epitope binding.
Immuno-EM analysis of baculoviral progeny of BV-E2/p17
In order to confirm the reality of this surface exposure,
samples of extracellular medium of BV-G2/p17- and
BV-E2/p17-infected Sf9 cells were analyzed by isopycnic
ultracentrifugation in sucrose-D2O gradients, and frac-
tions sedimenting at 1.15-1.08 were deposited on grids,
immunogold labeled with anti-HA tag antibody, and
observed under the electron microscope. BV-G2/p17
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most immunogold labeling was found at distance from
BV particles, and corresponded to nonspecific, back-
ground labeling (not shown). The absence of anti-HA
labeling of BV-G2/p17 virions in immuno-EM was con-
sistent with the absence of detectable scFvG2/p17 pro-
tein in the extracellular medium, as mentioned above.
Under the same experimental conditions however, anti-
HA tag immunogold labeling was found to be associated
with virions of BV-E2/p17 (Figure 6). The immuno-EM
analysis therefore confirmed that scFvE2/p17 molecules
were truely incorporated into the baculoviral envelope.
Such incorporation of foreign proteins into the baculo-
viral envelope has already been described with human
membrane glycoprotein CAR [41].
Immunological functionality and topology of scFvE2/p17
displayed on the baculoviral envelope
The observation that BV-displayed scFvE2/p17 was
accessible to anti-HA tag antibodies in immuno-EM
analysis strongly suggested that the C-terminal HA tag
was oriented outwards. This orientation was already
suggested by IF microscopy of intact cells expressing
scFvE2/p17 (refer to Figure 2A, i). The next experiments
were designed to assess the topological orientation of
the scFvE2/p17 molecule in the baculoviral envelope,
and, more importantly, to determine the degree of
accessibility of its antigen-binding regions. BV-E2/p17
virions were immobilized on ELISA plate and probed
with anti-HA tag antibody. The positive reaction indi-
cated that the carboxyterminal region of scFvE2/p17
was exposed at the surface of the virions (Figure 7a),
and that the insertion of scFvE2/p17 in the baculoviral
envelope mimicked the orientation of class II membrane
glycoproteins, with the aminoterminal region anchored
in the baculoviral envelope, as depicted in Figure 7b.
The antigen binding activity of BV-displayed scFvE2/
p17 was then determined by ELISA, using immobilized
H6MA-CA protein or synthetic peptide p17.1. In this
assay, BV-E2/p17 virions displaying scFvE2/p17 were
used as the equivalent of primary antibodies, and bound
virions were detected using monoclonal antibody direc-
ted towards the baculoviral glycoprotein GP64. Both
H6MA-CA protein and p17.1 peptide were recognized
by BV-E2/p17 virions (Figure 7c and 7d), which indi-
cated that the BV-displayed scFvE2/p17 molecules
retained their antigen-binding capacity.
BV-display of HA-tagged anti-CD147 scFv-M6-1B9
ScFv expressed in recombinant BV-infected insect cells
are not naturally or spontaneously addressed to the
baculoviral envelope, and different methods have been
developed to obtain baculoviral envelope insertion of
various scFv molecules, including fusion to GP64 or to
1.15 - d - 1.18  
(a) WB / anti-gGP64 
(b) WB / anti-HA tag 
m  (kDa) 
GP64 - 
- 105 
-  75   
-  50
scFvE2/p17 -  
  (30 kDa) 
-  50
-  37 
-  25  
Figure 5 BV display of scFvE2/p17 (BV-E2/p17). Samples of culture medium of Sf9 cells infected with BV-E2/p17 were harvested at 72 h pi
and analyzed by isopycnic ultracentrifugation in sucrose-D20 gradients, as described under Materials and Methods. Gradient fractions were
analyzed by SDS-PAGE and Western blotting, using (a) monoclonal antibody to the baculoviral GP64 envelope glycoprotein for detection of
baculovirus progeny, and (b) anti-HA tag monoclonal antibody for detection of scFvE2/p17.
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Page 13 of 21VSV-G stem [16-21]. Although scFvE2/p17 did not con-
tain any consensus signal peptide for membrane addres-
sing, we postulated that in Sf9 cells, the N-terminal
octadecapeptide sequence
1MEASLAAQAAQIQLVQSG
18
(abbreviated N18E2), was responsible for the intracellular
trafficking and targeting of scFvE2/p17 to the site of BV
budding, where it became inserted into the baculoviral
envelope. To test this hypothesis, N18E2 was fused to
the N-terminus of a non-related scFv, the HA-tagged
scFv-M6-1B9, which recognizes the membrane glycopro-
tein CD147 [38,39]. When expressed in HeLa or 293
cells, scFv-M6-1B9 occurred as an active anti-CD147
intrabody, provoking the intracellular retention of CD147
and the blockage of its surface expression [38,39].
Our resulting chimeric scFv construct, abbreviated
scFv-N18E2/M6, was expressed in Sf9 cells using a
recombinant BV vector (BV-N18E2/M6). ScFv-N18E2/
M6 molecules were detected in significant levels at the
surface of nonpermeabilized cells harvested at 48 h pi, as
for scFvE2/p17 (refer to Figure 2B). The baculoviral pro-
geny from BV-N18E2/M6-infected cells was then isolated
by ultracentrifugation and analyzed by ELISA (not
shown) and immuno-EM (Figure 8) using anti-HA tag
antibody. Both methods showed the accessibility of the
HA tag at the surface of BV particles. In the electron
micrograph shown in Figure 8d, two baculovirus particles
were seen as a V-shape dimer pointing to one gold grain.
This might represent the cross-linking of two particles
via the two Fab domains of a single antibody molecule,
although it could not be excluded that one antibody
would bind to one particle, while the other would be in
close proximity.
We also tested the antigen-binding capability of BV-dis-
played chimeric scFv-N18E2/M6, using the recombinant
50 nm 100 nm
100 nm
BV
a
50 nm 50 nm
e
b c
df
50 nm
Figure 6 Immuno-electron microscopy of BV particles carrying scFvE2/p17 (BV-E2/p17). Samples of baculovirus progeny recovered from
the culture medium of Sf9 cells infected with BV-E2/p17 and harvested at 72 h pi were deposited on grids and negatively stained with uranyl
acetate. Specimens were reacted with anti-HA tag monoclonal antibody, followed by anti-mouse IgG antibody coupled to 20-nm colloidal gold
grains. Different fields are presented in panels (a) to (f). Arrow in (a) points to a gold grain associated with a BV particle (BV). In (f), two gold
grains are seen associated with one BV particle.
Kitidee et al. BMC Biotechnology 2010, 10:80
http://www.biomedcentral.com/1472-6750/10/80
Page 14 of 21CD147-BCCP fusion protein as immobilized antigen in
ELISA, as previously described [39]. The data showed that
the chimeric scFv-N18E2/M6 molecules present at the
surface of BV particles conserved their antigen-binding
function and their specificity towards CD147 (Figure 9).
These results suggested that the fusion of the N18E2 pep-
tide to scFv-M6-1B9 was able to confer to the chimeric
scFv-N18E2/M6 protein the capacity to be addressed to
the BV budding sites at the plasma membrane and to be
incorporated into the baculoviral envelope. They also sug-
gested that N18E2 could function as a universal N-term-
inal signal peptide for BV-display of functional scFv of
biological interest. A scheme of the general strategy of
stepwise construction of BV particles displaying scFv
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Figure 7 Topology and functionality of BV-displayed scFvE2/p17 molecules. Baculoviral progeny recovered from the culture medium of Sf9
cells infected with BV-E2/p17 was isolated by ultracentrifugation. (a), BV-E2/p17 virions were immobilized on ELISA plate and reacted with anti-
HA tag monoclonal antibody and peroxidase-labeled complementary antibody. Controls were from left to right, respectively: uncoated well, well
coated with antigen with no BV addition, and well coated with antigen with addition of irrelevant baculovirus particles (CAR-displaying BV
CAR;
[41]). (b), Schematic model of scFvE2/p17 molecule displayed at the surface of a BV particle. GP64, baculoviral envelope major glycoprotein. BV-
E2/p17 virions were reacted in ELISA with immobilized antigen, (c) H6MA-CA-embedded p17 epitope, or (d) synthetic peptide p17.1. Average of
three separate experiments, m ± SEM; (*), P < 0.05); (**), P < 0.01).
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Page 15 of 21molecules of interest equiped with our signal octadecapep-
tide N18E2 is presented in Figure 10.
Discussion
Despite several recent studies, little information is avail-
able at the molecular level on the molecular factors and
mechanisms involved in the secretory pathway of insect
cells in general, and the lepidopterian Sf9 cells in parti-
cular [46]. Secreted recombinant proteins are usually
obtained by fusion of the protein of interest to the
N-terminal leader peptide of the honeybee pro-mellitin
(MBM-SP) [47,48]. However, this strategy does not
always guarantee the secretion of the recombinant pro-
tein. For example, scSCR20, a MBM-SP-leaded scFv
100 nm
a
50 nm
b
100 nm 100 nm
c d
Figure 8 Immuno-electron microscopy of BV particles carrying chimeric scFv-N18E2/M6 (BV-N18E2/M6). Samples of baculoviral progeny
recovered at 72 h pi from the culture medium of Sf9 cells infected with BV-N18E2/M6 were deposited on grids and negatively stained with
uranyl acetate. Specimens were reacted with anti-HA tag monoclonal antibody, followed by anti-mouse IgG antibody coupled to 20-nm colloidal
gold grains. Different fields are presented in panels (a) to (d). (a), General view of a cluster of immunogold-labeled BV-N18E2/M6 particles. (b-d),
Enlargement of immunogold-labeled BV-N18E2/M6 particles.
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Page 16 of 21derived from an anti-African cassava mosaic virus
monoclonal antibody [49] was not secreted in the cul-
ture medium of BV-infected insect cell lines from Spo-
doptera frugiperda, Trichoplusia ni,a n dMamestra
brassicae. However, scSCR20 molecules were released at
high levels in the culture medum of Drosophila cell
lines stably expressing MBM-SP-fused scSCR20 [50].
Likewise, certain types of scFv expressed in insect cells
using recombinant BV have been recovered in the extra-
cellular medium although they lack an insect cell leader
p e p t i d e[ 5 1 ] .T h em o s tp r o b a b l ee x p l a n a t i o nw a st h a t
specific features of recombinant scFv, such as their own
N-terminal amino acid sequence or/and other down-
stream domain(s), can influence their behaviour in BV-
infected cells.
BV-display has been used for almost a decade for
immunisation purposes, gene delivery, or development
of eukaryotic libraries [14,17,52,53]. Conventional BV-
display involves baculoviral envelope glycoprotein GP64
manipulations [17,18,52], or the use of the VSV-G stem
[16,17,20,21]. This differs from the incorporation of for-
eign proteins or glycoproteins into the baculoviral envel-
ope without fusion to GP64, such as the envelope
incorporation and display of functional human beta-2
adrenergic receptor (ß2AR) described in an earlier study
[54]. In a more recent work, we demonstrated the
incorporation of the human CAR glycoprotein into the
baculoviral envelope. CAR is the high affinity receptor
for adenovirus serotype 5 (Ad5) and is a resident glyco-
protein of the human cell plasma membrane. The bacu-
loviral envelope-incorporated CAR was fully functional
at the surface of BV
CAR virions, and enabled the forma-
tion of BV
CAR-Ad5 complexes, mediated by the interac-
tion between the adenoviral fiber and CAR. We have
used this strategy of BV
CAR-Ad5 duo formation to trans-
duce Ad5-refactory cells [41].
It was relatively easy to conceive that human ß2AR
and CAR molecules, even though expressed in heterolo-
gous system, could be displayed on the baculoviral
envelope since both are resident membrane glycopro-
teins. It was rather unexpected for scFvE2/p17, which
was an artificial molecule extrinsic to the BV-insect cell
system. Moreover, in the case of scFvE2/p17, the scFv
molecule was not constructed for membrane targeting,
in contrast to scFvG2/p17 which carried the specific
Met-Gly dipeptide signal for N-myristoylation by
N-myristoyl-transferases. Comparison of the amino acid
sequences of scFvE2/p17 and scFvG2/p17, which both
lacked any consensus leader peptide, showed that they
only differed by three residues at their N-terminus, M
(EAS)L for scFvE2/p17, versus M(G)L for scFvG2/p17.
The results of these minor sequence changes were
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Figure 9 Functional analysis of BV-displayed chimeric scFv-N18E2/M6. The antigen-binding capacity and specificity of chimeric scFvE2/M6
displayed on the BV particle envelope was assessed by indirect ELISA, as described in a previous study [38,39]. Aliquots of BV-N18E2/M6 and
control BV-E2/p17 particles recovered from BV-infected Sf9 cells were added to CD147-BCCP-linked avidin-coated wells, and incubated for 1 h at
RT. After washing steps, bound viral particles were detected by addition of anti-baculoviral envelope glycoprotein GP64 in TBS-BSA. Average of
three separate experiments, m ± SEM. (**), P < 0.01.
Kitidee et al. BMC Biotechnology 2010, 10:80
http://www.biomedcentral.com/1472-6750/10/80
Page 17 of 21Nhe I
Hind III
HA 
N18E2 
scFv coding sequence   scFv 
Nhe I Hind III
(1) 
(2) 
pBlueBac4.5 
pBlueBac4.5-scFv 
(3)
Linearized BV DNA 
Cross-over  Cross-over 
Recombinant BV DNA - scFv 
Selection, amplification, and 
 isolation of BV particles  
(4) HA 
BV-displayed, 
HA tagged scFv  N18E2  
VL VH 
VL VH 
GP64
Figure 10 Generation of recombinant BV vector designed for display of scFv using the N18E2 signal peptide. Shown is the stepwise
construction and isolation of BV-N18E2/scFv, a recombinant BV designed to expose at its surface scFv molecules of interest equiped with the
signal octadecapeptide N18E2. Step (1) : PCR amplification of the scFv coding sequence, using a Fw 5’-primer containing a Nhe I site and the
N18E2 coding sequence, and Rev 3’-primer encoding a HA tag and a Hind III site. Step (2) : insertion of N18E2-scFv-HA-encoding DNA fragment
into the baculoviral intermediate plasmid pBlueBac4.5, digested with Nhe I and Hind III. Step (3) : cotransfection of insect cells with pBlueBac4.5-
N18E2-scFv-HA and linearized baculoviral DNA, and homologous recombination. Step (4) : Isolation of plaques positive for recombinant
baculoviral clone harboring N18E2-scFv-HA (e.g. blue plaque selection); amplification and isolation of recombinant BV expressing N18E2-scFv-HA,
and displaying N18E2-scFv-HA on the baculoviral envelope.
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Page 18 of 21drastic in terms of scFv solubility, cell compartmentali-
zation and extracellular release. Recombinant scFvG2/
p17 protein expressed in Sf9 cells was inexploitable
since it was insoluble and trapped in the membrane
pellet.
Recombinant scFvE2/p17 however was recovered
simultaneously under two different forms: (i) as soluble
scFv molecules from lysates of BV-infected Sf9 cells,
and (ii) as BV-displayed scFv in the culture medium of
the BV-infected Sf9 cell cultures. Both forms could be
used as biological tools for different purposes. Soluble
scFvE2/p17 could serve in conventional diagnostic
assays for HIV-1 Gag detection, through specific recog-
nition of the conserved MAp17 epitope. MAp17 func-
tions as a structural component of HIV-1 virions, but
also as a viral cytokine which binds to a cellular recep-
tor, p17R [55,56], when released by HIV-infected cells.
I nt h ec a s eo fB V - d i s p l a y e ds cFvE2/p17, the potential
applications would be different. For example, if one con-
siders the virokine properties of soluble MAp17 and the
importance of inflammatory response at the mucosal
sites of HIV-1 entry [55,56], one could envisage to use
pelletable, BV-displayed scFvE2/p17 in experimental
models of infected mucosae to deplete soluble MAp17
from the extracellular medium, or/and to compete with
MAp17 for binding to p17R.
To assess the role of the N-terminal domain of
scFvE2/p17 in the process of membrane addressing and
scFv display on the baculoviral envelope, we fused the
N-terminal octadecapeptide
1MEASLAAQAA-
QIQLVQSG
18 (abbreviated N18E2) to another bioactive
scFv molecule, scFv-M6-1B9. The ligand of scFv-M6-
1B9 is M6, also called CD147 [38,39], a transmembrane
glycoprotein highly expressed in various types of malig-
nant cells [57] and tumors, e.g. nasopharyngeal carci-
noma [58]. CD147 acts as an inducer of extracellular
matrix metalloproteinases (EMMPRIN is another acro-
nym for CD147) to promote tumor growth, invasion,
metastasis and neoangiogenesis, and is a prognostic
marker for invasiveness in prostate cancer [59] and thyr-
oid carcinoma [60]. CD147 is also involved in athero-
sclerosis plaque instability [61] and in the regulatory
inhibition of starvation-induced autophagy in human
hepatoma cells [62].
We expressed the chimeric scFv-N18E2/M6 molecule
in recombinant BV-infected Sf9 cells, and found that the
BV progeny displayed scFv-N18E2/M6 on the baculo-
viral envelope. This suggested that the N-terminal octa-
decapeptide N18E2 carried the function required for
BV-display of scFv molecules, and could be considered
as a BV envelope addressing/anchoring signal peptide.
This was further supported by the comparison of the
structural domains of scFv downstream of the N18E2
peptide: scFv-N18E2/M6 and scFvE2/p17 differed by the
successive order of their variable regions, VL-linker-VH
from the N- to C-terminus in scFv-M6-1B9, versus VH-
linker-VL in scFvE2/p17. This implied that the nature of
the variable region downstream of N18E2 had little
influence, if any, on the membrane addressing of chi-
meric, N18E2-fused scFv.
Although the molecular mechanism of cell trafficking
of our chimeric scFv-N18E2/M6 molecule still remained
to be elucidated in molecular terms, our present data
provided a novel concept and platform for engineering
scFv molecules competent for BV-display.
Conclusion
In the present study, we identified a N-terminal octade-
cameric peptide sequence, N18E2, which mediated the
plasma membrane addressing and anchoring of scFv
into the baculoviral envelope, and acted as a BV-envel-
ope display signal. N18E2 could therefore be used in a
general technology for BV-display of bioactive molecules
such as scFv. In previous studies, we provided evidence
that scFv-M6-1B9 was biologically active as an intra-
body, and could be used to diminish the expression of
CD147 at the surface of human cells [38,39]. The data
presented here showed that scFv-M6-1B9 was also func-
tional when displayed on the BV vector envelope. One
might therefore envisage to use scFv-N18E2/M6-display-
ing BV particles as CD147-targeted vectors in future
protocols of cancer biotherapy, to transfer therapeutic
genes (e.g. suicide genes or proapoptotic genes) to
CD147-overexpressing malignant cells. Since the baculo-
viral envelope glycoprotein GP64 is a low specificity
attachment protein which allows BV to enter a wide
variety of cells originating from mammalian or non-
mammalian species [14,41], it will be necessary to block
the GP64 binding activity of such vectors, and/or place
the desired therapeutic gene under the control of a
tumor-specific promoter, in order to avoid any bystan-
der effect on cells of the surrounding tissues.
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